NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 262 filers reported holding NEKTAR THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $3,096,000 | -14.2% | 180,438 | 0.0% | 0.10% | -18.5% |
Q1 2021 | $3,609,000 | +17.7% | 180,438 | 0.0% | 0.12% | +14.8% |
Q4 2020 | $3,067,000 | -29.7% | 180,438 | -31.4% | 0.11% | -34.1% |
Q3 2020 | $4,364,000 | -28.4% | 263,079 | 0.0% | 0.16% | -29.3% |
Q2 2020 | $6,093,000 | +29.7% | 263,079 | 0.0% | 0.23% | +9.4% |
Q1 2020 | $4,696,000 | -23.3% | 263,079 | -7.3% | 0.21% | -8.6% |
Q4 2019 | $6,123,000 | +18.5% | 283,679 | 0.0% | 0.23% | +3.1% |
Q3 2019 | $5,167,000 | -48.8% | 283,679 | 0.0% | 0.22% | -45.4% |
Q2 2019 | $10,093,000 | +5.9% | 283,679 | 0.0% | 0.41% | +6.5% |
Q1 2019 | $9,532,000 | +207.3% | 283,679 | +200.6% | 0.39% | +191.0% |
Q4 2018 | $3,102,000 | -76.1% | 94,384 | -55.6% | 0.13% | -71.7% |
Q3 2018 | $12,952,000 | +40.5% | 212,469 | +12.6% | 0.47% | +34.3% |
Q2 2018 | $9,218,000 | -30.3% | 188,769 | +51.6% | 0.35% | -32.0% |
Q1 2018 | $13,231,000 | +63.7% | 124,517 | -81.4% | 0.52% | +36.2% |
Q3 2014 | $8,082,000 | – | 669,600 | – | 0.38% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |